@article{7c59092053c8428cae0a664724ecc547,
title = "An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling",
abstract = "Over the past decade, chikungunya virus (CHIKV) has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La R{\'e}union CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.",
keywords = "Adenovirus, Chikungunya, Oral, Tablet, Vaccine",
author = "Dora, {Emery G.} and Rossi, {Shannan L.} and Weaver, {Scott C.} and Tucker, {Sean N.} and Roberto Mateo",
note = "Funding Information: Vaxart, Inc. funded this study, and virus reagents were supported by the WRCEVA through NIH grant R24AI120942 . Funding Information: We would like to thank the Animal Resource Center at UTMB for their support during the animal studies. We are also grateful to Dr. Robert Tesh and the WRCEVA for supplying CHIKV strain 99569. We thank Jonathan Lindbloom and Ciaran Scallan for discussions about cloning strategy and performing vaccine expansion. We thank Katie Hodgson and Christina Joyce for technical assistance with mice and assays. Thanks to Debora Tingley for critical review of the manuscript. Funding for this work was supported by Vaxart Inc. Funding Information: We would like to thank the Animal Resource Center at UTMB for their support during the animal studies. We are also grateful to Dr. Robert Tesh and the WRCEVA for supplying CHIKV strain 99569. We thank Jonathan Lindbloom and Ciaran Scallan for discussions about cloning strategy and performing vaccine expansion. We thank Katie Hodgson and Christina Joyce for technical assistance with mice and assays. Thanks to Debora Tingley for critical review of the manuscript. Funding for this work was supported by Vaxart Inc. RM, EGD, and SNT are current employees and/or own stock in Vaxart, the sponsor of the studies. RM, SNT, SCW, and SLR designed the studies. EGD designed, constructed, and performed experiments. EGD and RM performed experiments and analyzed the data. RM wrote the paper. Vaxart, Inc. funded this study, and virus reagents were supported by the WRCEVA through NIH grant R24AI120942. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",
year = "2019",
month = may,
day = "27",
doi = "10.1016/j.vaccine.2019.04.069",
language = "English (US)",
volume = "37",
pages = "3146--3150",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "24",
}